EP1009432A4 - Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t - Google Patents

Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t

Info

Publication number
EP1009432A4
EP1009432A4 EP98930097A EP98930097A EP1009432A4 EP 1009432 A4 EP1009432 A4 EP 1009432A4 EP 98930097 A EP98930097 A EP 98930097A EP 98930097 A EP98930097 A EP 98930097A EP 1009432 A4 EP1009432 A4 EP 1009432A4
Authority
EP
European Patent Office
Prior art keywords
adaptive
composition
immune responses
preventing graft
lymphocyte immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98930097A
Other languages
German (de)
English (en)
Other versions
EP1009432A1 (fr
Inventor
David M Harlan
Alan D Kirk
Stuart J Knechtle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Navy
Wisconsin Alumni Research Foundation
Original Assignee
US Department of Navy
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Navy, Wisconsin Alumni Research Foundation filed Critical US Department of Navy
Publication of EP1009432A1 publication Critical patent/EP1009432A1/fr
Publication of EP1009432A4 publication Critical patent/EP1009432A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP98930097A 1997-06-11 1998-06-10 Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t Withdrawn EP1009432A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4938997P 1997-06-11 1997-06-11
US49389P 1997-06-11
PCT/US1998/011910 WO1998056417A1 (fr) 1997-06-11 1998-06-10 Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t

Publications (2)

Publication Number Publication Date
EP1009432A1 EP1009432A1 (fr) 2000-06-21
EP1009432A4 true EP1009432A4 (fr) 2004-07-07

Family

ID=21959563

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98930097A Withdrawn EP1009432A4 (fr) 1997-06-11 1998-06-10 Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t

Country Status (6)

Country Link
EP (1) EP1009432A4 (fr)
JP (1) JP2002504120A (fr)
AU (1) AU748533B2 (fr)
CA (1) CA2291338A1 (fr)
IL (1) IL133070A0 (fr)
WO (1) WO1998056417A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
JP2002533118A (ja) * 1998-12-29 2002-10-08 ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ Ｔ細胞レセプター使用を改変するためのｃｄ４０係合の使用
ES2286006T3 (es) * 1999-01-08 2007-12-01 Wisconsin Alumni Research Foundation Prevencion del rechazo cronico a transplante mediante combinacion de inmunotoxinas y bloqueadores de la coestimulacion.
JP2003520828A (ja) * 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
EP1284747A2 (fr) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions et procedes pour obtenir une suppression immune
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02012157A (es) 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
EP1935427B1 (fr) 2000-07-03 2018-03-07 Bristol-Myers Squibb Company Utilisations des molécules mutantes solubles CTLA4
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CN100574803C (zh) * 2001-01-31 2009-12-30 拜奥根Idec公司 免疫调节抗体在治疗肿瘤性疾病中的用途
EP1241249A1 (fr) * 2001-03-12 2002-09-18 Gerold Schuler Lymphocytes T CD4+CD25+ régulateurs provenant du sang humain
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
JP7788711B2 (ja) 2018-06-22 2025-12-19 株式会社Junten Bio 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法
US12139537B2 (en) 2018-06-22 2024-11-12 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
US12234287B2 (en) 2018-06-22 2025-02-25 Junten Bio Co., Ltd. Method for eliciting infectious immunological tolerance
JP2025038261A (ja) * 2022-02-08 2025-03-19 学校法人順天堂 他家移植方法及び拒絶反応抑制方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034633A1 (fr) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501815A (ja) * 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034633A1 (fr) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELWOOD E T ET AL: "LONG-TERM MURINE SKIN ALLOGRAFT SURVIVAL WITH PERIOPERATIVE CTLA4-IG AND ANTI-GP39: THE ROLE OF CD4+ T CELL.S", SURGICAL FORUM, CHICAGO, US, vol. 47, 1996, pages 427 - 429, XP002037031, ISSN: 0071-8041 *
GRIGGS N D ET AL: "THE RELATIVE CONTRIBUTION OF THE CD28 AND GP39 COSTIMULATORY PATHWAYS IN THE CLONAL EXPANSION AND PATHOGENIC ACQUISITION OF SELF-REACTIVE T-CELLS", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 183, no. 3, 1 March 1996 (1996-03-01), pages 801 - 810, XP002043672, ISSN: 0022-1007 *
LARSEN C P ET AL: "LONG-TERM ACCEPTANCE OF SKIN AND CARDIAC ALLOGRAFTS AFTER BLOCKING CD40 AND CD28 PATHWAYS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 381, no. 6581, 30 May 1996 (1996-05-30), pages 434 - 438, XP002037035, ISSN: 0028-0836 *
SCHAUB M ET AL: "SYNERGISTIC EFFECT OF CD-40L/CD40 AND CD28/B7 BLOCKADE IN MURINE EAE", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 99, no. 1, PART 2, 1997, pages S206, XP002037033, ISSN: 0091-6749 *
See also references of WO9856417A1 *

Also Published As

Publication number Publication date
EP1009432A1 (fr) 2000-06-21
CA2291338A1 (fr) 1998-12-17
AU748533B2 (en) 2002-06-06
AU7956798A (en) 1998-12-30
JP2002504120A (ja) 2002-02-05
WO1998056417A1 (fr) 1998-12-17
IL133070A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
EP1009432A4 (fr) Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t
AU4922785A (en) Method for separating bovine lactoferrin from cow's milk and purifying same
EP0949982A4 (fr) Procede et dispositif ameliores pour la preparation d'elements particulaires ou solides
EP0862564A4 (fr) Composes photoactivables pour la prevention de l'hyperplasie intimale et d'autres maladies
KR970701773A (en) Refining oil compositions
DZ1958A1 (fr) Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation.
EP0886471A4 (fr) Procede et composition pour induire une tolerance orale chez les mammiferes
EP0756827A3 (fr) Préparation pour l'alimentation
ITTO971019A0 (it) Attrezzo multifunzione per l'apertura di contenitori alimetari e non.
AU2945795A (en) DNA encoding an 18 Kd CDK6 inhibiting protein
DZ2141A1 (fr) Procédés intermédiares pour la préparation de 1-benzyl-4-(5,6-diméthoxy-1-indanone)-2-yi)méthylpipéridine.
FR2597362B1 (fr) Procede et installation de separation des constituants d'une suspension.
ITBO960254A0 (it) Metodo ed unita' per l'ordinamento di prodotti
IL102725A0 (en) Method for identifying and enumerating lymphocytes
EP0924985A4 (fr) METHODE POUR INHIBER L'EXPRESSION DE Fas
EP0844017A4 (fr) Procede de preparation d'un emulsifiant et composition emulsionnee
EP0853890A4 (fr) Composition alimentaire contenant du lactose pour nourrissons
HU9602274D0 (en) Detergent composition containing graft copolymer
EP0749988A3 (fr) Méthode pour la préparation de copolymères de cyclooléfines
MD940145A (ro) Bautura spirtoasa "fortuna" si procedeu de preparare a acesteia
GB2242689B (en) Method for refining titanium
FR2742084B1 (fr) Procede et dispositif d'usinage electrochimique de pieces en serie
FR2715280B1 (fr) Latte de renfort et de soutien pour articles d'ameublement ou autres types de sièges.
FR2665850B1 (fr) Machine de nettoyage in situ de rampes d'abreuvoirs suspendues.
EP0712206A3 (fr) Système d'attaque pour thyristors blocables

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040525

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 37/08 B

Ipc: 7A 61P 37/06 B

Ipc: 7C 07K 16/28 B

Ipc: 7C 07K 16/00 B

Ipc: 7A 61K 39/395 A

17Q First examination report despatched

Effective date: 20041201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050412